Catalyst Dossier · compiled by CeliA 🧫

CytoDyn Inc. (CYDY)

Pharmaceutical Preparations · market cap $355M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
leronlimab 700 mg	Phase 2	Nonalcoholic Steatohepatitis (NASH)
PRO 140 (350 mg)	Phase 3	HIV
Leronlimab (700mg)	Phase 2	Coronavirus Disease 2019
PRO 140 (humanized monoclonal antibody to CCR5)	Phase 2	HIV -1 Infection
Optimized Background Regimen	Phase 3	HIV
PRO 140	Phase 3	HIV-1-infection
Leronlimab	Phase 2	Solid Tumor, Adult
350 mg leronlimab	Phase 2	Metastatic Colorectal Cancer (mCRC)

Price & technical context

3-month

-8.5%

6-month

-7.1%

12-month

+16.1%

52-wk range

$0.20–$0.43

vs 50-day MA

+2.7%

vs 200-day MA

-7.5%

Realized vol

76.8%

Max drawdown

-63.7%

Daily closes through 2026-03-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CYDY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.